By Ryan M. Thomas
Every biotech claims to be transformative. Few prove it. This fall, Eyam did.
In just the last quarter, three global partners: the Gates Foundation, Medicines for Malaria Venture, and a Top 5 animal health company put our Gemini platform to the test. These aren't press release partnerships, they're real-world deployments, funded with hard dollars, designed to validate Gemini across species, diseases, and regulatory environments.
Why does that matter?
Because each deal is a force multiplier. Technically, they generate data that de-risks Gemini. Commercially, they prove demand for delivery systems that can scale. Strategically, they open doors to verticals where lipid nanoparticles (LNPs), cold chains, and dosing complexity have blocked access.
Most importantly, they show that Gemini isn't just viable, it's necessary to deliver the next generation of life saving biologics.
In one new study, we'll address a core limitation in modern biotech: targeted tissue delivery. If successful, Gemini could deliver long-acting therapeutics directly to the source of disease, a breakthrough even monoclonals and mRNA haven't achieved at scale.
And this progress isn't just scientific, it's financial.
Most biotechs take 6–7 years to generate revenue. Eyam did it in year four. That revenue is now fueling internal programs, reducing dilution, and compounding value for shareholders. Every partner dollar extends our runway, advances our pipeline, and strengthens our negotiating leverage without touching the cap table.
Where We're Headed: A Platform Built for the Next Decade
The biotech roadmap is becoming clearer: 2025 marks the start of a decade of vertical-specific bidding wars. Obesity now. Dermatology in 2026. Pulmonary, cardiometabolic, neuroinflammation, regeneration, and programmable RNA after that. And Eyam is well positioned to capture these markets.
Eyam's Gemini delivery system, or biologics shuttle, isn't a single-product play. It's delivery infrastructure designed to meet the moment—and the next decade.
- In dermatology, Gemini's naked nucleic acid delivery enables localized treatments without systemic toxicity or LNPs.
- In pulmonary and fibrosis, its stability and mucosal compatibility offer a path to low-cost respiratory biologics.
- In cardiometabolic and neuroinflammation, Gemini supports long-acting, tunable payloads that aim to reach hard-to-treat systems.
- And by 2030, when the field pivots to regeneration, synthetic immunity, and programmable RNA, Gemini will already be proven, modular, and ready to deploy for longevity treatments.
Others will scramble to retrofit platforms for each new wave, but Eyam won't need to because we've built Gemini to scale across them.
This is one of our competitive edges: not just early traction, but moving to category leadership, and not just platform validation, but platform velocity.
Final Call: Join Us Before the Next Inflection Point
We're closing what may be our last non-instutional round before the end of the year, and before our major inflection points arrive. We have less than $1M remaining to fill the round. That capital accelerates us to upcoming catalysts: data from large animal trials, new licensing deals, additional global health deployments, and positioning for clinical trials.
If you've been watching and reading from the sidelines wondering when the next investment opportunity might be, now is the time. The next inflection points are already in motion. Once they hit, the opportunity window closes.
Let's build the future of delivery.